Tagrisso's potency is demonstrated through its effectiveness in treating specific types of non-small cell lung cancer (NSCLC). It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) [1].
How does Tagrisso work?
Tagrisso targets EGFR mutations that drive cancer growth [2]. It is particularly effective against the T790M resistance mutation, which can develop after initial treatment with other EGFR TKIs [1][3].
What types of lung cancer does Tagrisso treat?
Tagrisso is approved for the treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or EGFR exon 21 L858R mutations as detected by an FDA-approved test [2]. It is also used for patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR TKI therapy [1][3].
When does Tagrisso's patent expire?
Information on Tagrisso's patent expiry can be found on DrugPatentWatch.com [4]. Patent and exclusivity information is crucial for understanding potential market competition from generic or biosimilar versions.
Who makes Tagrisso?
Tagrisso is manufactured by AstraZeneca [1].
How does Tagrisso compare to other lung cancer treatments?
Tagrisso represents a significant advancement in targeted therapy for EGFR-mutated NSCLC. Clinical trials have shown its superior efficacy compared to older EGFR TKIs in previously untreated patients, demonstrating higher progression-free survival rates and improved objective response rates [2][3].
What are the risks or side effects of Tagrisso?
Common side effects of Tagrisso include diarrhea, rash, dry skin, and stomatitis [1]. More serious risks can include interstitial lung disease, heart problems, and liver problems [1].
What is the price of Tagrisso?
Pricing information for Tagrisso is variable and depends on factors such as insurance coverage, pharmacy, and location. Patients seeking cost details should consult their healthcare provider or insurance plan.
Are there any clinical trials for Tagrisso?
Ongoing clinical trials continue to explore Tagrisso's efficacy in different patient populations and treatment settings, as well as its potential in combination therapies.
What is the outlook for patients treated with Tagrisso?
For patients with EGFR-mutated NSCLC, Tagrisso has significantly improved outcomes, offering a targeted approach that can control disease progression and improve quality of life [2][3].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/